Amyotrophic lateral sclerosis (ALS) has historically posed unique challenges for gene-
therapy-based approaches, due to a paucity of therapeutic targets as well as the difficulty of …

In the fatal disease—amyotrophic lateral sclerosis (ALS)—upper (corticospinal) motor
neurons (MNs) and lower somatic MNs, which innervate voluntary muscles, degenerate …

RNA-binding proteins (RBPs) are emerging as important effectors of the cellular DNA
damage response (DDR). The RBP FUS is implicated in RNA metabolism and DNA repair …

Neurodegenerative diseases are disabling and fatal neurological disorders that currently
lack effective treatment. Neural stem cell (NSC) transplantation has been studied as a …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the
death of both upper and lower motor neurons (MNs) in the brain, brainstem and spinal cord …

Since the discovery of Cu/Zn superoxide dismutase (SOD1) gene mutation, in 1993, as the
first genetic abnormality in amyotrophic lateral sclerosis (ALS), over 50 genes have been …

Insulin-like growth factor 2 (IGF2) emerged as a critical mechanism of synaptic plasticity and
learning and memory. Deficits in IGF2 in the brain, serum, or cerebrospinal fluid (CSF) are …

In the 30 years since the first report of parental imprinting in insulin-like growth factor 2 (Igf2)
knockout mouse models, we have learnt much about the structure of this protein, its role and …

ALS is characterized by progressive inability to execute movements. Motor neurons
innervating fast-twitch muscle-fibers preferentially degenerate. The reason for this …

A motor unit (MU) comprises the neuron cell body, its corresponding axon and each of the
muscle fibres it innervates. Many studies highlight age‐related reductions in the number of …